(NASDAQ: IVVD) Invivyd's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Invivyd's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast IVVD's revenue for 2024 to be $15,023,864,912, with the lowest IVVD revenue forecast at $4,558,759,344, and the highest IVVD revenue forecast at $33,034,488,000. On average, 2 Wall Street analysts forecast IVVD's revenue for 2025 to be $19,610,923,801, with the lowest IVVD revenue forecast at $17,319,982,058, and the highest IVVD revenue forecast at $21,901,865,544.
In 2026, IVVD is forecast to generate $35,401,959,640 in revenue, with the lowest revenue forecast at $35,401,959,640 and the highest revenue forecast at $35,401,959,640.